High and low molecular weight heparins do not modify red blood cell aggregability in vitro

Related Experiment Video

Updated: Oct 9, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

M Martínez1, A Vaya, C López-Camacho

  • 1Department of Clinical Pathology, University La Fe Hospital, Valencia, Spain. martinez_mar@gva.es

Clinical Hemorheology and Microcirculation
|February 24, 2001
PubMed

The usefulness of heparins as anticoagulants has been demonstrated, but their effects on hemorheological parameters, such as erythrocyte aggregability, are under discussion. If the heparins had adverse effect on erythrocyte aggregability, its use would be especially undesirable in patients with pathologies involving red blood cell hyperaggregability as is the case of cardiac disease. In the present study we examine the in vitro effect of unfractionated and fractionated heparins on red blood cell aggregability. The results show that heparins do not increase this rheological parameter but show a slight tendency to lower it.

More Related Videos

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

Controlled Microfluidic Environment for Dynamic Investigation of Red Blood Cell Aggregation10:27

Controlled Microfluidic Environment for Dynamic Investigation of Red Blood Cell Aggregation

Published on: June 4, 2015

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...